Loading…
Spruce Biosciences, Inc. is projected to rise to $63.89 by 2027, a +28% move from its current price of $50.07. SPRB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $48.41 | $50.11 | $51.88 | +0.08% |
| Jul 14 | $47.76 | $50.15 | $52.67 | +0.17% |
| Jul 15 | $47.28 | $50.20 | $53.30 | +0.25% |
| Jul 16 | $46.88 | $50.24 | $53.84 | +0.34% |
| Jul 17 | $46.54 | $50.28 | $54.33 | +0.42% |
| Jul 18 | $46.23 | $50.33 | $54.78 | +0.51% |
| Jul 19 | $45.96 | $50.37 | $55.20 | +0.59% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $45.96 | $50.37 | $55.20 | +0.59% |
| Week 2 | $44.51 | $50.67 | $57.68 | +1.19% |
| Week 3 | $43.49 | $50.97 | $59.73 | +1.80% |
| Week 4 | $42.69 | $51.27 | $61.58 | +2.40% |
| Week 5 | $42.02 | $51.58 | $63.30 | +3.01% |
| Week 6 | $41.46 | $51.88 | $64.94 | +3.62% |
| Week 7 | $40.96 | $52.19 | $66.51 | +4.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH).
The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd.
to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Spruce Biosciences, Inc. trades in the Healthcare sector with the SPRB ticker. The current price is $52.36 and the company has a market cap of $144.11M. It holds a rank of 4040 in market positioning.
The 30-day forecast shows a mixed near-term path, with 2026 expected to range from a low of $47.10 to a high of $77.24 and an average around $52.36, with a neutral sentiment. Over the longer horizon, the forecast transitions to bullish momentum from 2027 onward, with 2027 averaging $65.72 and 2028 averaging $73.99, climbing further through 2029 ($71.70) and into 2030 ($60.79), with substantial upside anticipated by 2040 ($118.86) and 2050 ($180.95). Max forecast values extend to $397.13 by 2050, indicating strong longer-term upside potential.
A major floor 15.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.9% below — buyers have tended to step in here.
The nearest ceiling, 11.6% above — a clean break opens room to run.
A major ceiling 40.8% above — clearing it would confirm fresh momentum.
Key SPRB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SPRB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $50.85 | Sell | $51.00 | Sell |
| MA 10 | $52.43 | Sell | $51.53 | Sell |
| MA 20 | $51.74 | Sell | $51.75 | Sell |
| MA 50 | $52.66 | Sell | $53.64 | Sell |
| MA 100 | $56.60 | Sell | $65.61 | Sell |
| MA 200 | $74.71 | Sell | $229.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.30 | Neutral |
| Stoch RSI (14) | 9.35 | Buy |
| CCI (20) | -66.82 | Neutral |
| Williams %R (14) | -95.56 | Info |
| MACD (12,26,9) | -0.14 | Sell |
| ROC (12) | -3.97 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 4.44 | Buy |
| TRIX (15) | -0.03 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 33.70 | Neutral |
| Momentum (10) | -2.70 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 49.90 | Buy |
| ADX (14) | 8.74 | Neutral |
| ATR (14) | 1.56 | Info |
The 30-day technical picture is NEUTRAL with a 14-day RSI of 50. The 50-day simple moving average is $55.22 and the 200-day simple moving average is $71.68. Support is at $47.10 and resistance at $59.00.
The 30-day range spans from $39.96 to $68.60, indicating a wide but shallow trading band. Annualized volatility sits at 80%, underscoring elevated near-term risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $47.10 | $50.07 | $70.73 | 0% | Neutral | |
| $49.59 | $63.89 | $87.80 | +28% | Bullish | |
| $51.98 | $69.45 | $99.84 | +39% | Bullish | |
| $49.31 | $67.91 | $101.12 | +36% | Bullish | |
| $45.01 | $63.69 | $97.66 | +27% | Bullish | |
| $44.68 | $64.81 | $101.94 | +29% | Bullish | |
| $49.68 | $73.76 | $118.69 | +47% | Bullish | |
| $59.77 | $90.70 | $148.98 | +81% | Bullish | |
| $58.47 | $90.62 | $151.67 | +81% | Bullish | |
| $55.38 | $87.57 | $149.14 | +75% | Bullish | |
| $71.62 | $124.28 | $227.59 | +148% | Bullish | |
| $100.40 | $205.70 | $418.18 | +311% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $47.10 | $50.07 | $59.64 | +0.00% |
| August 2026 | $43.00 | $51.14 | $62.71 | +2.13% |
| September 2026 | $45.09 | $54.09 | $67.26 | +5.78% |
| October 2026 | $44.65 | $53.98 | $67.91 | -0.21% |
| November 2026 | $43.50 | $52.94 | $67.24 | -1.93% |
| December 2026 | $45.07 | $55.18 | $70.73 | +4.24% |
Click any year to see its month-by-month SPRB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SPRB price prediction for 2026 points to an average of $50.07 (low $47.10, high $70.73) — a potential gain of 0% on today's $50.07. Price action looks broadly range-bound.
In 2027, SPRB is projected to trade between $49.59 and $87.80, averaging $63.89 — a potential gain of +28% from today's $50.07. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Spruce Biosciences, Inc.'s 2028 outlook centres on $69.45, within a $51.98 to $99.84 range. That is up +9% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, SPRB could reach as high as $101.12, with a base case around $67.91 and support toward $49.31 — roughly +36% from $50.07. Buyers look set to stay in control over this stretch.
Expect SPRB to range from $45.01 to $97.66 through 2030. The $63.69 average target implies a +27% move from current prices. That is -6% versus the projected 2029 average. Momentum favours further upside here.
The SPRB price prediction for 2031 points to an average of $64.81 (low $44.68, high $101.94) — a potential gain of +29% on today's $50.07. Buyers look set to stay in control over this stretch.
In 2032, SPRB is projected to trade between $49.68 and $118.69, averaging $73.76 — a potential gain of +47% from today's $50.07. That is up +14% on the projected 2031 average. Momentum favours further upside here.
Spruce Biosciences, Inc.'s 2033 outlook centres on $90.70, within a $59.77 to $148.98 range. That is up +23% on the projected 2032 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, SPRB could reach as high as $151.67, with a base case around $90.62 and support toward $58.47 — roughly +81% from $50.07. Momentum favours further upside here.
Expect SPRB to range from $55.38 to $149.14 through 2035. The $87.57 average target implies a +75% move from current prices. That is -3% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The SPRB price prediction for 2040 points to an average of $124.28 (low $71.62, high $227.59) — a potential gain of +148% on today's $50.07. Momentum favours further upside here.
In 2050, SPRB is projected to trade between $100.40 and $418.18, averaging $205.70 — a potential gain of +311% from today's $50.07. That is up +66% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in SPRB today (≈ 19.972039 SPRB) could be worth
$4,108.29
+$3,108.29 (+311%) by 2050 · US Dollar
Based on the average projected SPRB price of $205.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SPRBwould be worth at today's price.
$1,000 invested in SPRB on Jul 10, 2025 (≈ 2.435312 SPRB) would be worth
$121.94
-$878.06 (-87.8%) today · 0.12× · US Dollar
Based on a SPRB entry price of $410.63 vs. today's $50.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $52.51 | $953.53 | -4.6% |
| 1 month ago | $47.13 | $1,062.38 | +6.2% |
| 3 months ago | $63.63 | $786.89 | -21.3% |
| 6 months ago | $77.8 | $643.57 | -35.6% |
| 1 year ago | $410.63 | $121.94 | -87.8% |
| All time (5.0y) ago | $58,556.25 | $0.86 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SPRB forecast.
Our base-case forecast reaches $100.00 around 2040.
Implied market cap at $100.00: $275.23M
In the year-by-year forecast, 2026 shows a neutral path with min $47.10, avg $52.36, max $77.24 and ROI of 0. The momentum shifts to bullish territory from 2027 onward, with 2027 averaging $65.72 (ROI 25.5) and 2028 averaging $73.99 (ROI 41.3), then 2029 averaging $71.70 (ROI 36.9) and 2030 averaging $60.79 (ROI 16.1). The multi-year arc continues through 2031 ($64.17), 2032 ($71.69), 2033 ($84.00), 2034 ($89.36), and 2035 ($86.64) with rising sentiment.
The forecast extends to 2040 ($118.86; ROI 127) and 2050 ($180.95; ROI 245.6), both labeled BULLISH, signaling substantial longer-term upside potential despite shorter-term fluctuations. These are estimates and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
avg $60.79, min $41.05, max $97.55, ROI 16.1, sentiment NEUTRAL.
Forecasts show neutral in 2026 and bullish momentum from 2027 onward, with 2027 avg $65.72 (ROI 25.5), 2028 avg $73.99 (ROI 41.3), 2029 avg $71.70 (ROI 36.9), and 2030 avg $60.79 (ROI 16.1). These are estimates and not guarantees.
Yes, the 2028 forecast maximum is $110.45.
avg $180.95, max $397.13, ROI 245.6, sentiment BULLISH.
current price $52.36, market cap $144.11M, rank 4040.
Spruce Biosciences, Inc. Community Discussion
0Share your Spruce Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.